Posts tagged ‘ASCO Chicago’

ASCO 2011 Annual Meeting Conference Coverage

June 3rd, 2011

Daedalus

Sally Church on Pharma Strategy Blog is aggregating the tweets from the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Twitter hashtag #ASCO11.

If you are unable to attend, you can follow what’s happening on Pharma Strategy Blog.

In Sally’s video preview of ASCO 2011, she talks about ovarian cancer, metastatic melanoma and soft tissue sarcoma. The video is well worth watching. We especially like the 20 second animated intro sequence! Sally will be writing from ASCO on Pharma Strategy Blog and on twitter as @MaverickNY.

Pieter Droppert has also published an ASCO preview on Biotech Strategy Blog focused on prostate cancer. He is excited about data that will be presented on the use of circulating tumor cells (CTC) as a biomarker. Pieter will be tweeting from ASCO as @3NT.

If you are attending ASCO we look forward to meeting you at what is set to be an exciting conference, otherwise do follow the action on Pharma Strategy Blog.

Preview of ASCO 2011 Annual Meeting #ASCO11

May 31st, 2011

Daedalus

3013235262 8f75c04656 300x133 Preview of ASCO 2011 Annual Meeting #ASCO11

Photo Credit: Nimesh Madhaven

This Friday sees the start of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The meeting runs from June 3-7.

On Pharma Strategy Blog, Sally Church shares her thoughts on what she expects to be hot news at ASCO this year.

In her ASCO11 video preview Sally discusses clinical trial presentations in ovarian cancer, metastatic melanoma and soft tissue sarcoma. You can watch Sally’s video below and read more on Pharma Strategy Blog.

Icarus Consultants will be attending ASCO (along with 30,000 others), so if you are interested in meeting up, please contact us.

ASCO 2011 Olaparib and Cabozantinib are two new products to watch

May 24th, 2011

Daedalus

The countdown is underway for the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7^th. Over 30,000 attendees are expected and more than 4,000 abstracts will be presented.

What’s hot at the meeting is what everyone is asking? Sally Church is preparing a video blog (vlog) with her thoughts that will be posted on Pharma Strategy Blog soon.

In the meantime, two new products to watch out for are:

Cabozantinib (XL184). This new product from Exelixis may have potential in advanced prostate cancer with phase II data showing a dramatic effect on bone metastases, making it a potential competitor to denosumab. You can read more about the ASCO data on Biotech Strategy Blog.

Olaparib. Just when we thought that PARP inhibitors were ineffective after the failure of iniparib in breast cancer, there’s dramatic data at ASCO showing AstraZeneca’s olaparib prolongs remission in serious ovarian cancer. You can read more on Pharma Strategy Blog.

The focus of ASCO 2011 is “Patients, Pathways, Progress”. We’ll be writing more about the meeting over the next few weeks, so do check back for more details.

How resistance occurs to BRAF inhibitors such as PLX 4032 (vemurafenib)

May 13th, 2011

Daedalus

Icarus Consultants’ oncology expert, Sally Church has written extensively about BRAF inhibitors, and why melanoma patients develop resistance to PLX4032.

In a post on Pharma Strategy Blog, Sally reviews further research on mechanisms of resistance to BRAF inhibitors such as PLX 4032 (vemurafenib). Published in OncoTarget (an open access cancer journal), the article describes ERK dependent and ERK independent methods by which resistance occurs.

Sally notes that “as our knowledge of the science of metastatic melanoma improves, so do our opportunities for therapeutic intervention and improvement in outcomes.”

Metastatic melanoma is expected to be a hot topic at the forthcoming annual meeting of the American Society of Clinical Oncology (ASCO) that Icarus Consultants will be attending.

You can read more on Pharma Strategy Blog.